Clinical trial
A Multi-center, Single Arm, Phase II Study of Adjuvant Imatinib (Glivec®) in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor ( GIST)
NCT01172548 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Single Arm, Phase II Study of Adjuvant Imatinib (Glivec®) in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor ( GIST)
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2008
- Completion date
- March 31, 2014
- Enrollment
- 132 (actual)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.